Evidence map›Paper›PMID 39228730›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Randomized Crossover Clinical Trial of Nicotinamide Riboside and Coenzyme Q10 on Metabolic Health and Mitochondrial Bioenergetics in CKD.

Armin Ahmadi, Ana P Valencia, Gwénaëlle Begue, Jennifer E Norman, Sili Fan, Blythe P Durbin-Johnson, Bradley N Jenner, Matthew D Campbell, Gustavo Reyes, Pankaj Kapahi and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Armin AhmadiDepartment of Medicine, Division of Nephrology, University of California, Davis, CA, USA.
Ana P ValenciaDepartment of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, USA.
Gwénaëlle BegueKinesiology Department, California State University, Sacramento, CA, USA.
Jennifer E NormanDepartment of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, CA, USA.
Sili FanDepartment of Biostatistics, School of Medicine, University of California, Davis, CA, USA.
Blythe P Durbin-JohnsonDepartment of Biostatistics, School of Medicine, University of California, Davis, CA, USA.
Bradley N JennerDepartment of Biostatistics, School of Medicine, University of California, Davis, CA, USA.
Matthew D CampbellDepartment of Radiology, University of Washington, Seattle, WA, USA.
Gustavo ReyesDepartment of Radiology, University of Washington, Seattle, WA, USA.
Pankaj KapahiThe Buck Institute for Research on Aging, Novato, CA 94945, USA; Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA, USA.
Jonathan HimmelfarbDepartment of Medicine, Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, WA, USA.
Ian H de BoerDepartment of Medicine, Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, WA, USA.
David J MarcinekDepartment of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, USA.
Bryan R KestenbaumDepartment of Medicine, Division of Nephrology, Kidney Research Institute, University of Washington, Seattle, WA, USA.
Jorge L GamboaSchool of Medicine, Vanderbilt University, Nashville, TN, USA.
Baback RoshanravanDepartment of Medicine, Division of Nephrology, University of California, Davis, CA, USA.

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · 1986 to 2025
$12.6M
Nutrition, Obesity and Atherosclerosis Training ProgramT32HL007028 · NHLBI · UNIVERSITY OF WASHINGTON · 1985 to 2025
$1.9M
Role of Mitochondrial Dysfunction in the Response to Exercise in Patients with Advanced Kidney DiseaseR01DK125794 · VANDERBILT UNIVERSITY MEDICAL CENTER · 2025 to 2025
$647k
NHLBI NIH HHS T32 HL007028NIDDK NIH HHS P30 DK017047NIDDK NIH HHS R01 DK101509NIDDK NIH HHS R01 DK125794NIDDK NIH HHS R03 DK114502
6 · The paper itself

Abstract

Background: Mitochondria-driven oxidative/redox stress and inflammation play a major role in chronic kidney disease (CKD) pathophysiology. Compounds targeting mitochondrial metabolism may improve mitochondrial function, inflammation, and redox stress; however, there is limited evidence of their efficacy in CKD. Methods: We conducted a randomized, double-blind, placebo-controlled crossover trial comparing the effects of 1200 mg/day of coenzyme Q10 (CoQ10) or 1000 mg/day of nicotinamide riboside (NR) supplementation to placebo in 25 people with moderate-to-severe CKD (eGFR <60mL/min/1.73 m Results: The (mean±SD) age, eGFR, and BMI of the participants were 61±11 years, 37±9 mL/min/1.73m Conclusion: Six weeks of NR and CoQ10 improved in oxidative stress, inflammation, and cell bioenergetics in persons with moderate to severe CKD.

Indexed as

clinical trialmetabolismNephrology

Identifiers

PMID39228730
PMCPMC11370499

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.